Kane Biotech Announces New Funding Granted from CanExport Program
August 01 2019 - 4:30PM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announced that it has
been approved for $50,000 CAD in funding from the Government of
Canada’s CanExport SMEs program. Kane will use this funding to
accelerate the growth of its bluestem line in new markets,
particularly Brazil (South America), China, and the UK (Europe).
CanExport SMEs is a program delivered by the Trade Commissioner
Service (TCS) of Global Affairs Canada in partnership with the
National Research Council’s Industrial Research Assistance Program
(NRC-IRAP). It provides direct financial assistance to small and
medium-sized businesses registered in Canada in order to help them
develop new export opportunities and markets.
Ray Dupuis, Chief Financial Officer of Kane Biotech, stated,
“Our team plans to use these funds for targeted marketing
activities in order to increase our visibility in the high-growth
markets of Brazil, China, and the UK. We have a number of exciting
initiatives underway to support our geographic expansion in
collaboration with local market leaders, and we’re grateful for
programs such as CanExport for their contribution towards achieving
our long-term goals.”
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (56 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com, or contact:
Marc Edwards |
|
|
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
Kane Biotech Inc. |
|
|
|
|
|
|
|
+1 (514) 910-6991 |
|
|
|
|
|
|
medwards@kanebiotech.com |
|
|
|
|
|
|
|
|
Ray Dupuis |
|
|
|
|
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
|
Kane Biotech Inc. |
|
|
|
|
|
|
|
+1 (204) 298-2200 |
|
|
|
|
|
|
rdupuis@kanebiotech.com |
|
|
|
|
|
|
|
|
Joe Green |
|
|
|
|
|
|
|
US. Investor Relations |
|
|
|
|
|
|
|
Edison Inc. |
|
|
|
|
|
|
|
+1 (646) 653-7030 |
|
|
|
|
|
|
jgreen@edisongroup.com |
|
|
|
|
|
|
|
|
Laine Yonker |
|
|
|
|
|
|
|
US. Investor Relations |
|
|
|
|
|
|
|
Edison Inc. |
|
|
|
|
|
|
|
+1 (646) 653 7035 |
|
|
|
|
|
|
lyonker@edisongroup.com |
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Sep 2023 to Sep 2024